Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI ...
A 9-month PSA <0.2 ng/mL after ADT initiation was associated with substantially better overall survival (adjusted HR 0.46) and lower progression risk versus not achieving it. Depth-to-threshold ...
The phase 3 CAPItello-281 trial (NCT04493853) met its primary end point by showing that the addition of capivasertib (Truqap) to abiraterone (Zytiga) and prednisone significantly improved radiographic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results